Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

BMW says new AI models can cut battery cell production time and material use by over 50% in key process steps.

Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...